Telavancin: A novel lipoglycopeptide antimicrobial agent

Attwood, R.J.; LaPlante, Kerry L.

doi:10.2146/ajhp070080

Cited by 40 publications

(16 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lipophilic moiety of telavancin interacts directly with the bacterial cell membrane, resulting in depolarisation and increased permeability of the cell membrane. As shown in this study, telavancin MICs have previously been reported to be two to eight times lower than corresponding vancomycin MICs [10].…”

Section: Discussionsupporting

confidence: 60%

Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin

Stuart¹,

John²,

Milburn³

et al. 2011

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 60%

Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin

Stuart¹,

John²,

Milburn³

et al. 2011

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Animal model data suggest efficacy in the treatment of bacteremia, endocarditis, meningitis, and pneumonia caused by gram-positive pathogens (1,16,19,20,28). Our findings suggest that future use of telavancin holds promise in treating infections caused by biofilm-producing staphylococci and enterococci and that it should be further evaluated for the treatment of biofilm-re-FIG.…”

mentioning

confidence: 84%

“…Telavancin possesses a second mechanism of action that causes rapid depolarization and loss of the functional integrity of the bacterial membrane (1,12). These two mechanisms of action may be implicated in the lower range of methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) MICs observed with telavancin (MIC range, 0.06 to 1.0 g/ml) compared to vancomycin (MIC range, 0.5 to 2 g/ml) (8,13).…”

mentioning

confidence: 99%

In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus , S . epidermidis , and Enterococcus faecalis Strains

LaPlante

Mermel

2009

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

We investigated the activities of telavancin and vancomycin against biofilm-producing Staphylococcus and Enterococcus strains. At clinically attainable concentrations, telavancin was active against bacteria embedded in biofilm (minimal biofilm eradication concentration [MBEC], 0.125 to 2 g/ml) and inhibited biofilm formation at concentrations below the MIC. Vancomycin did not demonstrate the same activity (MBEC, >512 g/ml) against Staphylococcus aureus and Enterococcus faecalis. Telavancin may have a unique role in biofilmassociated infections.Staphylococci and enterococci account for a large proportion of hospital-acquired infections, especially among patients with indwelling devices (17). These infections are often caused by biofilm-producing strains which are difficult to eradicate and which may cause bacteremia and metastatic infections (30).Telavancin is a new lipoglycopeptide antimicrobial agent with a core chemical structure similar to that of vancomycin yet modified to include a lipophilic side chain (15). Telavancin possesses a second mechanism of action that causes rapid depolarization and loss of the functional integrity of the bacterial membrane (1, 12). These two mechanisms of action may be implicated in the lower range of methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) MICs observed with telavancin (MIC range, 0.06 to 1.0 g/ml) compared to vancomycin (MIC range, 0.5 to 2 g/ml) (8, 13).Previous reports have suggested that telavancin is more effective than vancomycin against biofilm-forming S. aureus in a pharmacokinetic filter model (9). We compared telavancin and vancomycin activities by using previously described in vitro biofilm activity assays. The first assay evaluated each agent's activity in a preformed biofilm by using both a modified version and the standard version of the Calgary Biofilm Pin Lid Device (CBPD) (3,14). The second assay evaluated activity in preventing biofilm formation by planktonic isolates (14).( The medium used for biofilm growth was Bacto tryptic soy broth (TSB; Becton Dickinson, Sparks, MD) plus 1% glucose and 2% NaCl (14). All assays were run in quadruplicate, and cultures were incubated at 35°C. Conventional MICs and minimal bactericidal concentrations (MBCs) were determined in duplicate by using Clinical and Laboratory Standards Institute (CLSI) guidelines (5, 6).We used a modified version of the CBPD to determine the antimicrobial susceptibility of bacteria embedded in a 24-h biofilm to determine the minimum biofilm inhibitory concentration (MBIC) and the minimum biofilm eradication concentration (MBEC) (3). Briefly, a starting inoculum of 7 log 10 CFU/ml was established by the direct colony suspension method from a 24-h tryptic soy agar (TSA; Becton Dickinson, Sparks, MD) plate. This inoculum was then standardized with McFarland standards and validated by determination of viable counts on TSA plates. Biofilms developed on the pin lid (Immuno TSP; Nunc, Roskilde, Denmark) submerged in the inoculated broth at 35°C for 24 h on a rocking table (Boekel S...

show abstract

“…114 Although the telavancin MIC 90 was elevated against VRE, it was appreciably lower than that observed with vancomycin (MIC 90 > 256 µg/mL). 115 However, it is unknown if these differences in MIC will result in any clinical benefit because most vancomycin-resistant E faecium isolates possess the VanA gene. Its place in therapy is likely to be limited, and no clinical data in VRE bacteremia are available.…”

Section: Telavancinmentioning

confidence: 99%

Vancomycin-Resistant Enterococcal Bacteremia Pharmacotherapy

Patel

Gallagher

2014

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Telavancin: A novel lipoglycopeptide antimicrobial agent

Abstract: Telavancin is a promising new agent for gram-positive infections and may offer an alternative to vancomycin for MRSA-associated infections.

Cited by 40 publications

References 68 publications

Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin

Susceptibility patterns of coagulase-negative staphylococci to several newer antimicrobial agents in comparison with vancomycin and oxacillin

In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus , S . epidermidis , and Enterococcus faecalis Strains

Vancomycin-Resistant Enterococcal Bacteremia Pharmacotherapy

Contact Info

Product

Resources

About